All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Overview of CAR T-cell therapy in the management of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is characterized by autoreactive B cells producing autoantibodies against self-antigens, with some patients developing severe, refractory SLE (srSLE).1,2 For such cases, chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel treatment option.1 The process of CAR T-cell treatment is depicted in Figure 1.
Figure 1. Procedure of CAR T-cell treatment in SLE*
CAR, chimeric antigen receptor; SLE, systemic lupus erythematosus.
*Adapted from Lin, et al.1 Created with BioRender.com
Currently, there is a lack of clinical experience with CAR T-cell therapy in patients with SLE. In Figure 2, we summarize the ongoing clinical trials investigating various CAR T-cell therapies and a case series involving patients with srSLE in a compassionate use program.2-5
Figure 2. Overview of CAR T-cell therapies under investigation for management of SLE*
CAR, chimeric antigen receptor; CRS, cytokine release syndrome; cCAR, compound CAR; ds, double-stranded; ICANS, immune effector-cell associated neurotoxicity; Ig, immunoglobulin; LLDAS, Lupus Low Disease Activity State; LN, lupus nephritis; phGA, Physician Global Assessment; SAE, serious adverse event; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
*Data from Cortés Hernández, et al.2; Yuan, et al.3; PR Newswire.4; Taubmann, et al.5
|
Key learnings |
|
- Lin CJ, Lee YH, Shih PC, et al. From concept to reality: CAR-T therapy as a glimmer of hope for systemic lupus erythematosus patients. Int J Rheum Dis. 2023;26(11):2137-2140. DOI: 1111/1756-185X.14871
- Cortés Hernández J, Barba P, Linares Alberich M, et al. An open-label, multicenter, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T cell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: Preliminary results. Abstract #L13. American College of Rheumatology annual meeting (ACR Convergence) 2023; Nov 10-15, 2023; San Diego, US.
- Yuan Y, He S, Zhang W, et al. Novel BCMA-CD19 compound CAR-T (cCAR) targets B cells and plasma cells achieving immune reset and eliminates all autoantibodies in systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients resulting in long-term, medication-free remission. Abstract #1493. American College of Rheumatology annual meeting (ACR Convergence) 2023; Nov 10-15, 2023; San Diego, US.
- milestone for first U.S. patient dosed in phase 1 clinical trial of CD19 CAR T-cell therapy for lupus nephritis. https://www.prnewswire.com/news-releases/kyverna-therapeutics-announces-achievement-of-28-day-post-infusion-milestone-for-first-us-patient-dosed-in-phase-1-clinical-trial-of-cd19-car-t-cell-therapy-for-lupus-nephritis-301925488.html. Published Sep 13, 2023. Accessed Dec 4, 2023.
- Taubmann J, Müller F, Boeltz S, et al. Long term safety and efficacy of car-t cell treatment in refractory systemic lupus erythematosus - data from the first seven patients. Oral abstract #OP0141. European Alliance of Associations for Rheumatology Congress 2023; May 31-June 3, 2023; Milan, IT.
Newsletter
Subscribe to get the best content related to lupus delivered to your inbox